# A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

> **NCT03548467** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nykode Therapeutics ASA** · enrollment: 41 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumours

## Interventions

- **BIOLOGICAL:** VB10.NEO
- **DRUG:** Bempegaldesleukin

## Key facts

- **NCT ID:** NCT03548467
- **Lead sponsor:** Nykode Therapeutics ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-04
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548467, "A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03548467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*